News & Updates

AI combines histopathology tissue analysis and protein data to improve ovarian cancer treatment predictions

Our international research team has developed a novel approach that significantly improves predictions of how patients with High-Grade Serous Ovarian Cancer (HGSOC) will respond to platinum-based chemotherapy using pathological tissue images and proteomics data.

More information: Oz Kilim et al. Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction, NPJ Precision Oncology DOI: 10.1038/s41698-025-00808-w

New Publication in Nature Cancer

Our paper "ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer" was published in Nature Cancer. The study demonstrates that ALK-derived peptide vaccination can reverse immune escape in ALK-positive NSCLC, restoring T-cell recognition of tumor cells and providing a potential therapeutic strategy for patients with ALK-rearranged lung cancer.

Best Poster Award

Received the Best Poster Award at the DF/HCC Breast and Gynecologic Cancer Symposium, presented by Dana-Farber/Harvard Cancer Center. The award recognized our work on identifying DNA repair deficiency biomarkers with clinical relevance for ovarian and breast cancer treatment stratification.

Conference Presentation at Dana-Farber

Presented our work on DNA repair deficiencies at the Annual Symposium on Cancer Research at Dana-Farber Cancer Institute, Boston. The presentation covered novel computational approaches for detecting homologous recombination deficiency (HRD) and nucleotide excision repair (NER) defects across multiple cancer types using whole-genome sequencing data.

Research Milestone: 160+ Citations for HRD Method

Our method for estimating homologous recombination deficiency — implemented in the scarHRD R package — has now been cited in over 160 publications. The method is used by research groups worldwide to identify HRD-positive tumors, supporting companion diagnostic development for PARP inhibitor therapy in ovarian, breast, and prostate cancers.